PPARD and kidney disorder: Kirkby NS et al. found that renal blood flow is regulated by cyclooxygenase-2 (COX-2) activity through PPARδ-mediated renal vasodilator pathway involving prostacyclin, indicating the potential of COX-2/prostacyclin/PPARδ axis as a therapeutic target in renal disease [37].